Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary
November 17, 2020
Earnings Call Speaker Segments
Operator
operatorThanks, and hello everyone — welcome to the conference call covering Palatin Technologies' operating results for the first quarter of fiscal year 2021. Just a note that this call is being recorded. Before we get into our prepared remarks, please keep in mind that anything Palatin states which isn't a historical fact could constitute a forward-looking statement. Such statements rest on assumptions that might turn out to be accurate or might not, and actual outcomes could differ materially from what we anticipate because of various risks and uncertainties that have been discussed in the company's latest filings with the Securities and Exchange Commission. We ask that you weigh those risks and uncertainties carefully when you evaluate these forward-looking statements as well as Palatin's prospects. At this point, I'd like to hand today's call to our host, Dr. Carl Spana, Palatin Technologies' President and Chief Executive Officer. Sir, please go ahead.
Carl Spana
executiveThanks, and good morning everyone, and welcome to our first quarter fiscal year 2021 call for Palatin Technologies. I’m Dr. Carl Spana, President and CEO of Palatin. Joining me today is Steve Wills, who serves as Executive Vice President, Chief Financial Officer, and Chief Operating Officer at Palatin. During this call, we’ll be giving financial and operating updates. We truly hope you and your families remain safe and healthy as you cope with the life-altering changes that the COVID-19 pandemic has caused. At this point, I’ll hand things over to Steve, who will give the financial update along with an update on Vyleesi. Steve?
Steve Wills
executiveThanks, Carl, and good morning, everyone. Turning to the first quarter, which ended September 30, 2020: our net loss for that quarter came to $3.9 million, or $0.02 per share, versus a net loss of $4.5 million, or $0.02 per share, in the same quarter of 2019. Vyleesi gross sales from July 25 through September 30 totaled $809,100. We recorded negative $288,560 in Vyleesi net product revenue, with net meaning net of allowances and accruals. For the quarter we recorded no contract and license revenue, compared with $97,379 in the comparable quarter of 2019. Total operating expenses for the quarter were $3.7 million, which includes a $1.6 million gain on the license termination agreement with AMAG related to Vyleesi. That compares to $5 million — compared to 5 million of operating expenses in the comparable quarter of 2019. As of September 30, 2020, the company held $86.6 million in cash and cash equivalents and $5 million in accounts receivable, versus $82.9 million in cash and cash equivalents and no accounts receivable as of June 30, 2020, and no outstanding debt. With $86.6 million in cash and cash equivalents, Palatin is in a comfortable position to fund its anticipated operating results well through calendar year 2021.
Steve Wills
executiveOn the Vyleesi front, in July 2020 Palatin disclosed that it and AMAG Pharmaceuticals had agreed to end their licensing arrangement for the product by mutual consent. Through that termination deal, Palatin got back the full set of rights to develop and commercialize Vyleesi across North America. At closing, AMAG paid Palatin $12 million, and a further 4.3 million payment from AMAG is due to Palatin on March 31, 2021. Palatin took on every manufacturing agreement tied to Vyleesi, while AMAG handed over information and data plus all assets used solely for Vyleesi, inventory that already existed included. For a stretch of time, AMAG is furnishing specified transitional services to Palatin so that patients keep having access to Vyleesi and regulatory compliance holds up while the product moves back to Palatin. Palatin is paying AMAG back for the transition services at the costs both sides agreed on. Accounting for this transaction produced a $1.6 million gain on the license termination. As for commercial work on Vyleesi, the past few months have kept us quite occupied. Support for Vyleesi was, to some degree, quite limited across the first half of 2020 and before Palatin took the rights back. Among the things we have done that we see as very positive steps: we have firmed up the distribution network and its procedures. We have strengthened contact with prescribers and healthcare providers — prescribers and healthcare providers — by way of virtual meetings.
Steve Wills
executiveWe have boosted coverage for insurance reimbursement, and not long ago we launched a very targeted digital marketing plus telemedicine effort aimed at restoring awareness and demand with premenopausal women, using at first a geo-targeting strategy focused on leading prescriber and digital locations. Carl is going to go into more detail on a few of these items concerning Vyleesi and will also bring us a program update on the other programs Palatin has in development. Carl?
Carl Spana
executiveAll right, thank you, Steve. While we keep functioning through the COVID-19 pandemic, one of our main priorities has been keeping our employees, our patients, our healthcare providers, and partners safe. To that end, we put a work from home policy in place in March. It is still in force for our office staff. Our research laboratory, though, is open and running. Luckily, most of our key research and development partners are still operating, and through teleconferences and various online meeting platforms, we have managed to keep advancing our programs effectively. That said, we recognize that as activities resume, business activity could face further disruptions from a resurgence of the virus, which is happening right now across the country, and we will be ready for that possible outcome. As Steve noted, in July 2020 we re-acquired Vyleesi from AMAG Pharmaceuticals. As a reminder, AMAG's divestiture of Vyleesi stemmed from strategic and operational changes at AMAG, not from the potential value of Vyleesi. Steve has already covered some of the details of the Vyleesi commercial plan, but there are a number of accomplishments I want to emphasize. When we re-acquired in late July, marketing efforts had been limited and there had been only nominal focus on distribution and patient access to Vyleesi.
Carl Spana
executiveThe result has been a less-than-ideal patient experience along with highly unfavorable economics. Guided by Steve, we've put together a strong and highly motivated commercial group that moved quickly to tackle these problems. During the past quarter, we strengthened the Vyleesi distribution network, enhanced how patients fare by retraining our specialty pharmacies, and broadened insurance coverage. Beyond that, we're reaching out to healthcare providers via virtual office visits and virtual meetings. These efforts are producing a considerably improved patient experience, stronger ties with prescribers, and better economics, and they've built the groundwork for us to launch, as Steve noted, a selective geo-targeting marketing campaign. What has been achieved — and in my view at a record pace — has positioned us well to show Vyleesi's potential value in a cost effective way and to reach our ultimate goal of re-licensing Vyleesi to a committed partner, making sure Vyleesi remains available as a treatment option for premenopausal women with HSDD or hypoactive sexual desire disorder, along with a financial return on our investment. Moving forward, many of you are aware that Palatin's primary scientific focus is the melanocortin system, which plays a role in regulating energy balance, including food intake, sexual function, and resolution of inflammatory responses.
Carl Spana
executiveThe first melanocortin program we got across the finish line came from understanding how the melanocortin system helps regulate sexual function. That research effort led to the discovery of Vyleesi, and eventually the FDA approved it as the first on-demand treatment for premenopausal women who have hypoactive sexual desire disorder. Today our research is centered on creating drugs that harness the melanocortin system's capacity to resolve or dial down inflammation. We've come up with several drug candidates that, in preclinical models, have shown they may resolve a range of inflammatory conditions. And studies run by our team and by others have demonstrated that targeting immune cells with drugs that modulate the melanocortin system leads to resolution of pro-inflammatory processes. Those pro-resolution activities include mediating the conversion of immune cells from an inflammatory state to a regulatory one, inhibiting production of pro-inflammatory cytokines, such as TNF-alpha and interleukin-6, among others, and upregulating anti-inflammatory cytokines like interleukin-10. On top of that, the melanocortin system helps reduce the fibrotic response that arises as part of many inflammatory diseases. Fibrosis that stems from inflammatory disease carries long-term negative consequences for patients' health. So we believe melanocortin drugs will be broadly useful in treating inflammatory diseases.
Carl Spana
executiveWe've created drug candidates in the clinical stage for eye conditions including dry eye disease, additional ocular indications like non-infectious uveitis, and retinal disorders. We likewise maintain a clinical stage drug cabinet addressing gastrointestinal conditions such as ulcerative colitis. PL-9643, one of our melanocortin receptor agonists, launched a Phase 2 trial in dry eye disease with an eye drop formulation in January of 2020. Dry eye disease, referred to also as keratoconjunctivitis sicca, impacts the cornea and conjunctiva of the eye, producing irritation, redness, pain, and blurry vision. Its causes vary, and we believe that activating the melanocortin system locally will let PL-9643 reduce the inflammation behind many negative aspects of dry eye disease. By July of 2020, the study had reached full enrollment with 160 dry eye disease patients, and we remain on track for data in December of 2020. This study's primary objective is to supply the data needed to move PL-9643 ophthalmic solution forward into later stage clinical trials, which would begin in the first half of 2021. Since data are coming before year-end, I'd like to review the trial design in our regulatory strategy. Endpoints in dry eye disease clinical studies fall into two categories: signs and symptoms.
Carl Spana
executiveWhen we talk about a sign, that's objective evidence that disease is present—things like corneal lesions and tear production. Symptoms, on the other hand, are what patients actually feel as aspects of the disease, such as blurry vision and itchy eyes. Our PL-9643 Phase 2 study is a multicenter, randomized, controlled trial that compares PL-9643 against placebo over a 12-week treatment period. For the co-primary endpoints, one is a sign of dry eye disease—inferior corneal fluorescein staining—and the other is a symptom, ocular discomfort, measured on a validated zero scale. We've also built in a number of secondary endpoints that assess how PL-9643 affects both signs and symptoms of dry eye disease. Normally, a Phase 2 study would rely on just one primary endpoint alongside multiple secondary endpoints. But following our discussions with the FDA, we decided to go with co-primary endpoints, and the strategy behind that is that this Phase 2 study could potentially serve as one of the two required Phase 3 pivotal studies, provided both co-primary endpoints reach statistical significance. The study has been designed so that multiple outcomes can support the advances of PL9643. Those potential outcomes include statistical significance for one or both co-primary endpoints, or for other signs or symptoms in the primary or specific sub-populations that are part of the secondary endpoint analysis.
Carl Spana
executiveTaking that approach lowers the risk in Phase 2 and leaves open the chance that the Phase 2 trial could serve as one of the two pivotal Phase 3 studies that are required. Treating dry eye disease in the market is a sizable commercial opportunity, exceeding $2 billion in yearly sales, with continued growth driven by patient demographics. We think PL-9643's potential efficacy, together with its stable tolerability and safety profile, will permit substantial penetration of the dry eye market. Turning now to PL-8177, a pulmonary disease, specifically our COVID-19 program. In preclinical disease models, PL-8177 has shown anti-inflammatory activity as well as the capacity to shield lung tissue from fibrosis-related damage. As a possible therapy for patients infected with COVID-19, PL-8177 may lessen the inflammation in lung fibrosis tied to progressive disease. During the second quarter of calendar 2020, we held discussions with BARDA about PL-8177 as a possible treatment for patients with COVID-19 infections. Among the outcomes of that discussion was the advice that we advance PL-8177 and start talks with the FDA regarding a potential clinical study in COVID patients. In the second quarter of 2020, we submitted a pre-IND data package to the FDA and obtained detailed advice on what is required to move PL-8177 into clinical studies.
Carl Spana
executiveWith the PL-8177 COVID-19 plan we have in place right now, we're carrying out every activity required in order to file an investigational new drug application, or an IND, and to start clinical studies in COVID-19 patients. Those activities include things like developing the clinical protocol, choosing a CRO, identifying clinical trial sites, and manufacturing PL-8177 placebo and active doses. That said, because getting hold of the syringes required to manufacture the active and placebo doses has been delayed, the COVID-19 pandemic has affected our capacity to finish the manufacturing activities that are required. We expect that we won't be able to finish manufacturing PL8177 until the first half of 2021. Until those activities are done, filing an IND and starting a study with PL8177 won't be possible for us. As was discussed on earlier calls, a press release is included in our 10-K. The landscape for treating COVID-19 patients and for conducting clinical studies in them is changing quickly, and that affects the design of clinical studies in COVID-19 patients, their risk, and our ability to conduct them. Having weighed the risk and uncertainty involved in running COVID-19 clinical studies, the start of a PL8177 clinical study depends on our receiving external funding and operational support, and we are currently in the process of applying to government programs that offer that kind of support.
Carl Spana
executiveAt the start of this year, we submitted an application under the government's active program seeking support for PL8177, and a favorable review came through not long ago. Regrettably, though, we were told that the active program has stopped funding clinical programs at earlier stages and has set its priorities so that only Phase 3 programs receive funding. We are still pursuing additional forms of outside support and are hopeful that we will eventually secure successful backing for this program. For our retinal disease indication, the clinical trial is set to start during the second half of 2021. COVID-19's impact has pushed this back slightly, and we are putting the extra time to use by broadening our scientific knowledge of the melanocortin system and ocular diseases. Turning to the update on our oral colon release formulation of PL8177 as a treatment for ulcerative colitis and other inflammatory bowel diseases, we have carried out the required pre-clinical activities, and drug manufacturing for this program continues to be on schedule for launching a Phase 2 proof of mechanism study in the first half of 2021. And last, building on our research in the natriuretic peptide system, our drug candidate PL-3994, a naturally occurring peptide receptor A agonist, will be assessed in a Phase 2A clinical study involving heart failure patients with preserved ejection fraction.
Carl Spana
executiveThis clinical trial is being run jointly with 2 large academic medical centers, and the American Heart Association Grant is providing support for it. I'm pleased to share that we've started enrolling patients, and the first participant has received a dose. More details about our programs are available on our website, www.palatin.com. When the pandemic hit, the executive management employees and the board of directors moved quickly to reshape how we run the business, and we've managed to keep moving our programs forward. In dealing with COVID-19, we acted right away to protect our employees, patients, and health care partners. Our capacity to keep advancing our development programs, together with our healthy cash position, will let Palatin come out of the pandemic in a strong position. Our commercial work on Vyleesi has advanced considerably. Under Steve Wills's direction, we've built an excellent commercial team that addresses many of the deficiencies we inherited from AMAG Pharmaceuticals, and we've now started selective marketing of Vyleesi. We're continuing to collaborate with our partners in China and Korea, who are now moving Vyleesi into clinical studies and supporting their regulatory submissions aimed at eventual approval and sale of Vyleesi in those territories.
Carl Spana
executiveOur confidence in Vyleesi's worth for women dealing with HSDD remains strong, and we see this as a substantial chance to boost our company's value. For the larger Vyleesi program, we began and finished enrolling a Phase 2 clinical study. Data is expected on schedule in December, and we are getting ready to proceed should those results prove positive. Looking ahead to the remainder of 2021, we will keep managing the operational difficulties created by the COVID-19 pandemic. We hold a robust pipeline of novel clinical candidates, and our attention will stay fixed on moving them forward. Thanks to the research efforts finished over the past year, we are in position to launch clinical studies in COVID-19 patients, ulcerative colitis, and one or more ocular disease indications during 2021. To wrap up, I want to express gratitude to the Palatin team and all our development partners for how quickly they adapted to a new working environment and for their ongoing commitment to advancing Vyleesi commercial activities along with our other novel drug candidates. We will now take questions on the call.
Operator
operatorThanks. <<operator_script>> Our first question comes from John Newman at Canaccord.
John Newman
analystMorning, everyone. Thanks for taking my question. First off, I was just wondering how much longer AMAG is going to keep providing those transitional services — sorry, for Vyleesi. And then I also wanted to ask whether you could speak to possible licensing discussions around Vyleesi and what you would be looking for there. Thanks.
Steve Wills
executiveHi John, thanks for asking — this is Steve, and I’ll handle that one, with Carl coming in to add some color. The exact length of time is confidential, but it’s safe to say things will proceed in an orderly way. We worked out terms with AMAG; as you know, we consider that a very fair timeframe when it comes to transitional services, and that carries over as well — I think you’re likely aware that AMAG is set to be acquired by Covis. That deal, as I understand it, is aimed at closing very soon, possibly even this month. So we don’t anticipate any problems there. As for the re-licensing process for the U.S., or North America, we’re involved in several conversations and are trying to approach it in what we’d describe as a very direct manner, and the initial few months after the license ends and we get the rights back — as Carl did more than hint at during his presentation and prepared remarks — there was simply a great deal of work that needed to get done before we could, so to speak, have what we’d regard as substantive discussions and make progress. So that’s now in motion. For the most part, it’s fairly traditional.
Steve Wills
executiveWe want a partner active in women's health—a field with the infrastructure and the commitment. At Palatin we have considerable flexibility, since we're able to be a very supportive partner. Based on the company, its size, and its focus, we can take on CMC and anything along those lines in a good way, apart from commercial efforts, even though we're managing that at present. So I believe that leaves us able to be flexible. I think the work done previously—it's been under four months since we got the product back. And to be clear, the suit wasn't entirely tailored in that respect. So we do believe that at some point down the road we'll be able to seriously consider relicensing and make the best decision for the shareholders.
Carl Spana
executiveI think, John — and one of the things we've also accomplished, which will really help with licensing, is that we've really put an end to our reliance on AMAG. So a lot of things, such as manufacturing distributions, those agreements have already been moved over to Palatin. So a lot of the things that, you know, need to be in place so you can have a valuable license and a quick license turnover are really, you know, in the process of transitioning or have already transitioned from AMAG to Palatin, and as, you know, we've been saying, they needed attention, and now they've been cleaned up and they're working. So we'd like to be able to hand over to the partner, you know, something like a well-oiled machine that's up and running, so that this can just be dropped into the bag and they can just focus on the commercial activities. And I think that's how they'll get, you know, the maximum value for the product, and a lot of those things are already done, and I think before too long, we really won't depend on AMAG for much of anything.
John Newman
analystThanks a lot — that’s great.
Operator
operatorThanks. We'll now take our following question from Joe Pantginis at H.C. Wainwright.
Joe Pantginis
analystHey everyone, and thanks for the question. So first, building on what you mentioned earlier regarding AMAG and the sale to Covis, I just want to put the finishing touch on that point. So, number one, is there anything we should know about concerning the change of control? And then second, looking at the pipeline, you're looking for additional — you're looking for external funding for the COVID-19 program for 8177. So I figured this might be a good chance to give us a bit of a refresher, and give me a bit of a refresher too, on the preclinical data you currently have that provides encouragement for the program. Thanks.
Carl Spana
executiveOkay, sure — it's really just about handling the transition. We've already made contact — Steve has in fact already been in touch with Covis's senior management, and they've confirmed that they will, you know, be in place and keep supporting whatever other transitional services we need from them. So I don't think — we just believe it'll be minimal, with no effect from that transition, which is going to close shortly. Well, moving along on this, you pointed to PL8177 potentially as a therapy for COVID patients, and we'll take that in a couple of directions. So from a pre-clinical perspective, you know, it's clear to us that PL8177, across a variety of models, has demonstrated suppression of pro inflammatory cytokine production. What was quite interesting and quite encouraging for us was really the work done in a lung disease model — that's for interstitial pulmonary fibrosis — which is run as what's called the bleomycin model, one of the standard models that really examines how a drug affects lung fibrosis, which is really a key detriment in these inpatients. And we saw really nice success in reducing the fibrosis that occurs in lungs in that model.
Carl Spana
executiveThere's a solid body of preclinical evidence, from the anti-inflammatory side as well as the anti-fibrotic side, that gives strong backing for moving into clinical trials. And we've actually been reviewed under both the BARDA program and the ACTIV program, and those scientific reviews came back quite positive. The thing is, with so many compounds in the pipeline, and the preference for late-stage candidates, we end up getting excellent scientific reviews but then hearing, come back once you're ready for Phase 3. So in that vein, we've brought in a group that specializes in securing funding for programs like PL8177, and we're resubmitting grants and other applications to obtain additional support. Unfortunately, since manufacturing has been delayed somewhat, that gives us time to let these efforts unfold. Whether or not the financing comes through, we might decide not to proceed in COVID patients absent funding, but we genuinely believe in PL8177's value for treating acute lung diseases more broadly, and we'd consider perhaps shifting to a different indication that could be easier for us to reach, in terms of clinical trial sites and patients, which would be tougher to do with COVID patients right now without support.
Carl Spana
executiveWe do believe it will move ahead in lung disease in some form or another. It's just not clear which path we'd take until we actually work through the granting process and the external funding process.
Joe Pantginis
analystUnderstood. That's really useful. Thanks, everyone — I'm looking forward to quite a few significant catalysts coming up soon.
Operator
operatorThanks. We’ll take our next question from Michael Higgins at Ladenburg Thalmann.
Edward Marks
analystMorning. Edward here, on for Michael. Thanks, guys, for taking our questions. I'll begin with Vyleesi — it looks like there was a $1.1 million charge during the quarter, and that's what pushed net sales negative. I just want to check whether that's right, and whether that charge will recur, and on net margin, I'm wondering what we should be watching for over the coming quarters.
Steve Wills
executiveHi, this is Steve. So, that figure isn't right. I need to speak with our outside auditors about it. But it is accurate. AMAG's initial approach was focused on demand. They didn't — if you will, have certain procedures in place that would secure insurance reimbursement. That simply wasn't the original strategic approach. They intended to evolve into, if you will, putting those procedures in place that bring insurance reimbursement. They began by procuring coverage, broadening that coverage, and then the divestiture process got underway. So what you're seeing is, if you grasp how Vyleesi gets distributed and sold — the first script, and the script as defined, is for autoinjectors. Palatin subsidized it, and AMAG had done so previously, covering 100% of it. That means the patient's co-pay is zero dollars. Zero out of pocket for the first — for the script, the first script. For every later script, the refills, the out-of-pocket cost cannot go above $99. So what you've got is somewhat of a perfect storm at the moment, now that the product is back with us and we're broadening the coverage. And I believe we're achieving some quite substantial gains on that front.
Steve Wills
executiveBut the key thing is that we changed our procedures with the specialty pharmacies, and through that we're pursuing insurance reimbursement for every dose. So right now, you've got a really large amount of, let's call it offset—the rebates and allowances against, say, the positive gross, the gross sales—which for this period produced net sales. Going forward, that flips into positive sales, and ideally substantially positive sales. A bit lower in the statement, we also show cost of goods sold, and you can see we have a very strong margin. Even after we get certain things in place, with insurance reimbursement coming through and demand heading the right way, our gross profit margin is going to be above 90%. So the takeaway, Edward, is that this is a timing difference. We've fixed certain procedures and processes. They're now in place. And it grows each week and each month.
Edward Marks
analystOkay, that's great, and thanks for making that clear. One more thing on that same topic. It seems sales came in around 800,000, and you're looking at a $5 million run rate for the year. So are those early revenues driven by demand, or do they also factor in some stocking and destocking tied to the AMAG transition?
Steve Wills
executiveLook, here's our view — I wouldn't take what we saw between July 25 and September 30 and project it forward, as Carl pointed out in his prepared remarks, and I said there as well that certain things had to be finished before we could push ahead with the attack, the awareness, and the demand. Insurance coverage had to be broadened, and pre-certain procedures that enable insurance reimbursement had to be changed and fixed over at the specialty pharmacy level. So our stance is that demand is going to rise, and ideally by a meaningful amount as we move ahead. We also just recently kicked off this geo-targeting digital marketing campaign. And you might say, well, sure, recently — within the past few weeks. And even though we've had the product for a little under four months, launching that campaign any earlier would have made no sense; you don't want to drive demand up. And beyond that, it would negatively affect the kind of revenue dollars and cash dollars you're seeing as a manufacturer. So we think we're sitting in a really strong spot on that front as well, as we're attacking the <<inaudible>> going forward to get that upswing in the demand curve.
Carl Spana
executiveI'll try to explain this in my own way, since I'm not an accountant. Sadly, as Steve puts it, I'll say it more plainly: what we took over was a product that had essentially been abandoned. Its net sales were negative, you know. We couldn't put up with that. When we sell our fill of Vyleesi scripts, we have to make money. To accomplish that, we had to get a lot of pieces in place, and we have now done so. So at this point we're able to focus on growing demand, because rather than rising demand costing us money, we won't be making money. I don't know, perhaps I'm being a bit silly, but I figure when you sell something, you want to earn money on the sale. So we had to repair and set up the infrastructure that let us do that. That is now the situation. And it will grow as Steve said; again, those numbers will be modest. Our insurance coverage is good. And it's going to get even better once we're into the New Year. A great team is working alongside us. And we're broadening coverage, you know, nearly every day.
Carl Spana
executiveIs there anything else anyone would like to ask?
Edward Marks
analystYou pretty much answered what I was going to ask next. On the last call, you talked about the digital marketing campaign and the coverage, and you gave a few numbers on that. I was hoping you could say a bit about how much you're putting in, which sites you're considering for the digital marketing campaign, and then whether you can give any updates on the coverage versus what was said on last quarter's call?
Steve Wills
executiveHey, this is Steve. When we were taking the product back from AMAG, the coverage that was coming in was really advancing — it was in that 50% range. We managed to get it into the mid-60 range, and by mid-60 range I mean covered lives out there, which is the acronym people use, and we're pushing ahead aggressively. We've got a third party expert consultant helping us with this effort, and our goal is to clear 75%, if not 80%, by the first quarter of next year. So that's about as much specificity as I can offer on coverage, and it's always confidential regarding who's covering us, but the general rule of thumb is that there are five main covers, coverage groups that handle, if you will, 80% of covered lives. So we're in a pretty good position there. We aren't seeing any pushback once we get — once we get the right person and the right attention. This is a product that's on demand. We don't have any safety issues. The pricing and things of that nature — there's no push back in that regard.
Steve Wills
executiveIt's really just a timing difference once again. So what we intend to do is come to you — in Q1, that figure stood above 75% to 80% of covered lives.
Edward Marks
analystAlright, that's precisely…
Steve Wills
executiveOn the digital marketing side, we aren't running this as a full commercial operation. There's no salesforce in place, and Carl, myself, and plenty of others share the view that a salesforce would likely have only a limited effect during this phase of the pandemic. So what we're doing is leveraging digital marketing — the Facebooks, the Instagrams, telemedicine — and we consider the investment level sensible. For the first few months, it runs between $500,000 and perhaps $750,000, as you're building that foundation. After that, it will likely drop by around 50%. And as I said before, this is geo-targeting. Our view is that this amounts to an intensified proof of concept. We aren't going national. There are specific markets where we want to demonstrate that putting in the dollars produces impact, produces demand, and produces a value proposition when it comes to net sales — and that, in our view, places us in a far stronger position when it comes to re-licensing.
Edward Marks
analystAlright, that’s clear. Then one last question about 9643 and the Phase 3 as we move ahead — if you could give a bit of a timeline for the outlook? And could you also say something about the cost and how likely it is that you’ll partner on or keep this asset, depending on how the Phase 2 results come out going forward?
Carl Spana
executiveSo broadly speaking, if things turn out favorably and luck is on our side, we'd be running a complete Phase 3 program next year — and completing every activity for that full Phase 3 program would come to roughly $20 million. That covers all the extra manufacturing work, the validation tasks, the entire clinical effort, and getting to the point where those studies are finished; they'd wrap up next year. What's great about dry eye studies is how fast they go. So if we launch them during the first half of the year, they'll finish in the second half, and then you're ready to file. It's a really speedy program. And for a Phase 3 effort headed toward an NDA submission, it isn't especially costly — but it will land in that $20 million range to actually carry out everything we'd need to do, and then get ourselves in position to submit an NDA late next year or early in 2022.
Edward Marks
analystAll right, so my sense is that this is going to be handled internally by your own team, correct?
Carl Spana
executiveI mean, we — until we actually have the data and can look at it. We've certainly had — Steve has handled a lot of the business development work. And we've definitely held early conversations with potentially larger companies that would have interest in a dry eye product. But really, until you have the data and your regulatory path forward is entirely clear, you know, there isn't much you can do. You know, that was going to do a deal with us with data pending. So once that data comes out, we certainly will examine business development options, if they're available, and we'll go from there.
Edward Marks
analystAll right, that's great. Thanks, everyone. I'm finished on my end. I appreciate all the specifics.
Steve Wills
executiveAppreciate it, Ed.
Carl Spana
executiveThanks.
Operator
operatorThanks. That brings today’s question-and-answer portion to an end. I’ll now hand the call back to Carl Spana.
Carl Spana
executiveThank you, and thanks to everyone for joining the call. The questions we got were good ones — they helped us clear up what is happening at the company. We're eager to keep giving you updates as things develop. I would be surprised if we don't hold another call tied to the data that will come out from the dry eye disease study in December. We're looking forward to that, and to keeping all of you informed about the progress we're making here. The team here is working very hard, and many customers are coming and will keep coming. So thank you, stay safe, and have a great day.
Steve Wills
executiveI appreciate that.
Operator
operatorAppreciate it, everyone. That brings us to the end of today's teleconference. You're free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.